Imatinib Vocate (Imatinib)

Imatinib acts on BCR‑ABL driven malignancies and related kinase‑dependent tumors.

• Chronic myeloid leukemia (CML): reduces abnormal white‑cell proliferation and improves long‑term survival.
• Gastrointestinal stromal tumor (GIST): blocks KIT/PDGFRA signaling to inhibit tumor growth.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides targeted inhibition of BCR‑ABL to achieve disease control.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL tyrosine kinase, as well as KIT and PDGFRA kinases. By preventing phosphorylation of downstream substrates, it blocks proliferative and survival pathways that drive malignant cell growth, leading to apoptosis or cell‑cycle arrest in affected cancer cells.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, usually self‑limiting.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Severe neutropenia: marked reduction in white‑blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced cardiac output, especially in patients with pre‑existing disease.
• Pulmonary hypertension: increased pressure in lung arteries.
• Anaphylaxis: life‑threatening allergic reaction.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Patients should be monitored closely for safety concerns before and during therapy.

• Blood count monitoring: perform complete blood counts regularly to detect cytopenias.
• Liver function tests: assess hepatic enzymes periodically.
• Cardiac assessment: evaluate heart function in patients with known cardiac disease.
• Hypersensitivity: discontinue if severe allergic reactions occur.
• Pregnancy considerations: avoid use unless benefits outweigh unknown risks.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels, compromising efficacy.
• Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: imatinib can enhance anticoagulant effect; monitor INR.
• CYP2C8 substrates (e.g., repaglinide): may require dose adjustment.
• Diuretics causing hypokalemia: monitor electrolytes as imatinib can exacerbate low potassium.
• QT‑prolonging agents (e.g., sotalol): watch for additive cardiac conduction effects.